about
Na+ - and Cl- -coupled active transport of nitric oxide synthase inhibitors via amino acid transport system B(0,+)Structure and function of ATA3, a new subtype of amino acid transport system A, primarily expressed in the liver and skeletal muscleCarrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir AnalogueQuantitative time-lapse imaging-based analysis of drug-drug interaction mediated by hepatobiliary transporter, multidrug resistance-associated protein 2, in sandwich-cultured rat hepatocytes.The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells.Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaInvolvement of OCTN1 (SLC22A4) in pH-dependent transport of organic cations.Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924Transport characteristics of L-citrulline in renal apical membrane of proximal tubular cells.Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestineOrganic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.Impact of FDA-Approved Drugs on the Prostaglandin Transporter OATP2A1/SLCO2A1.Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs.OATP transporter-mediated drug absorption and interaction.Putative roles of organic anion transporting polypeptides (OATPs) in cell survival and progression of human cancers.Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer.OATP2A1/SLCO2A1-mediated prostaglandin E2 loading into intracellular acidic compartments of macrophages contributes to exocytotic secretion.Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs.[(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.Kinetic Evaluation of Determinant Factors for Cellular Accumulation of Protoporphyrin IX Induced by External 5-Aminolevulinic Acid for Photodynamic Cancer Therapy.Involvement of Concentrative Nucleoside Transporter 1 in Intestinal Absorption of Trifluridine Using Human Small Intestinal Epithelial Cells.Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters.Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2.A role of prostaglandin transporter in regulating PGE₂ release from human bronchial epithelial BEAS-2B cells in response to LPS.Total syntheses of (-)- and (+)-goniomitine.Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human.Hepatic uptake of gamma-butyrobetaine, a precursor of carnitine biosynthesis, in rats.Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.Characteristics of transcription-regulatory elements for gene expression from plasmid vectors in human trophoblast cell lines.Comparison of transgene expression mediated by several Fiber-modified adenovirus vectors in trophoblast cells.Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival.Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.Usefulness of kidney slices for functional analysis of apical reabsorptive transporters.
P50
Q28362810-4E45D6FF-23B2-4A03-AF13-AB1C13471CF3Q28577556-83D1B911-C237-496D-8A9B-5D5256F71D2AQ28833485-1C243D96-957B-483F-8E5D-C2A97B19554AQ33849667-5AF39C2D-6DB4-4650-ABA0-DC3C4C6DBBD6Q33896008-45348737-172A-4A1B-BDA9-268C0645E010Q34217728-2BD3C626-7569-4DC1-9FC0-FA4622BE7088Q34405146-C1E86414-E5AA-4CBD-91F9-BF234944E5FCQ34470786-309F0D61-2F2A-4A79-A640-20FC6D52E9C3Q34556812-491594CC-BDCB-466B-A6BA-1D97727A8CF4Q34674256-C2BCF46D-5589-4084-95A5-F9EC86F4CAEFQ34969284-6E191834-3756-471C-A34C-B22763DBE507Q35108153-12EADBF6-376C-47AC-9A04-D974F12AE8FBQ35141418-AD30F0EA-871F-4000-B83C-0BCE5EC3C367Q35829622-04732E96-C871-4E49-8ED5-E5B1D849343BQ36365176-E8553220-11FD-493D-A240-23859875167AQ37416153-35005A18-8C1E-422A-B8FE-AB06D6384AD9Q37883237-051E02A8-5B10-4087-924E-49EBA8698870Q37958162-D70D40AA-1290-4A72-A886-EEBD1D177433Q37970175-23BE2F87-4D26-4433-8BEA-E08794858077Q38141451-B7F9DAEA-6E8A-4F9D-B50C-BF5940C962BEQ38243217-DF975BC3-115F-4998-8E3F-6DF32F52F9CCQ38335459-4DF0B37A-B49B-4326-AC67-F81B95233464Q38827334-54F8AF3F-CAD7-4CC1-9EA5-05E601BEFF7BQ38833698-D906809F-1B96-4D55-9EDB-B8167B55E14DQ38843341-38A57BBA-B35C-40B4-B9D8-5988EB98146AQ38877129-54D56965-4A8D-483E-BF42-0A7E9F9A8118Q38883737-1F624EED-937A-4F24-9E81-0F51D2C1FBA1Q38983205-10070463-8BBB-48B3-A7B3-5A85A0C300C6Q39155744-89CC4BEB-F6E6-45F7-886D-D4E367F810A2Q39175800-1DEC8BE5-D142-46E4-8392-B1A908B4A854Q39581364-5578A1C4-455B-4E36-B7DC-954D2D176A04Q39734079-B145706F-7630-420D-92AF-8DEF171C12FEQ39812873-A0E5875D-35EC-43A9-BFE1-80F03E69B4D3Q40278791-092855AC-1C58-4376-A047-13F64539709CQ40294957-49B5B7F4-F733-46E0-AFAC-8D48311F8EA8Q40361941-C1707CE8-18A7-4548-89E5-B8F961FD2E81Q40463271-6ECEC9C5-77F3-40EC-B7EA-54E3A9BC889EQ40496905-CF128B98-826B-482B-90F2-746669EC4CD9Q40543176-3A6B9E2F-5295-4036-B93E-D2ACD2BDA486Q42373933-5DB49935-71E3-4540-B106-395ADCD6563E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Takeo Nakanishi
@ast
Takeo Nakanishi
@en
Takeo Nakanishi
@es
Takeo Nakanishi
@nl
Takeo Nakanishi
@sl
type
label
Takeo Nakanishi
@ast
Takeo Nakanishi
@en
Takeo Nakanishi
@es
Takeo Nakanishi
@nl
Takeo Nakanishi
@sl
prefLabel
Takeo Nakanishi
@ast
Takeo Nakanishi
@en
Takeo Nakanishi
@es
Takeo Nakanishi
@nl
Takeo Nakanishi
@sl
P1053
C-3891-2015
P106
P1153
35501085200
P21
P31
P3829
P3835
takeo-nakanishi
P496
0000-0002-6561-7138
P569
2000-01-01T00:00:00Z